Hims & Hers Health (NYSE:HIMS) Trading 2.9% Higher - Here's Why

Key Points

• Hims & Hers Health's stock price increased by 2.9%, reaching a last trading price of $45.23, though trading volume decreased by 67% compared to average volumes.
• Analysts have adjusted their ratings, with Citigroup maintaining a "sell," while TD Cowen downgraded from "buy" to "hold" and reduced the price target to $30.00.
• The company's recent earnings report showed a net margin of 9.63% with revenue up 72.6% compared to the previous year, but it fell short of consensus estimates, missing earnings per share by $0.01.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price was up 2.9% during trading on Friday . The stock traded as high as $45.10 and last traded at $45.23. Approximately 11,206,420 shares traded hands during trading, a decline of 67% from the average daily volume of 33,614,164 shares. The stock had previously closed at $43.96.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. TD Cowen lowered Hims & Hers Health from a "buy" rating to a "hold" rating and reduced their price target for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. Truist Financial dropped their price objective on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday. Piper Sandler reissued a "neutral" rating and issued a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Stock Performance

The company has a market cap of $10.06 billion, a P/E ratio of 55.66, a P/E/G ratio of 2.93 and a beta of 2.08. The firm has a 50 day moving average price of $51.92 and a 200-day moving average price of $45.76. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling

In related news, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total value of $3,214,800.00. Following the sale, the insider owned 169,940 shares of the company's stock, valued at approximately $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 660,000 shares of the business's stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the sale, the chief executive officer owned 2,214,769 shares of the company's stock, valued at approximately $112,023,016.02. This represents a 22.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,396,090 shares of company stock valued at $71,927,627 over the last 90 days. Company insiders own 13.71% of the company's stock.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently modified their holdings of the stock. Farallon Capital Management LLC raised its stake in shares of Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after acquiring an additional 8,364,000 shares during the last quarter. Geode Capital Management LLC grew its holdings in Hims & Hers Health by 1.5% in the second quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company's stock worth $236,622,000 after purchasing an additional 71,593 shares during the period. Invesco Ltd. grew its holdings in shares of Hims & Hers Health by 502.2% during the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company's stock valued at $127,237,000 after buying an additional 2,128,587 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Hims & Hers Health by 19.5% during the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company's stock valued at $71,969,000 after buying an additional 397,310 shares during the last quarter. Finally, Yong Rong HK Asset Management Ltd grew its holdings in shares of Hims & Hers Health by 41.2% during the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock valued at $70,920,000 after buying an additional 700,100 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.